Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

Jeffrey Crawford¹ · Carla M. M. Prado² · Mary Ann Johnston³ · Richard J. Gralla⁴ · Ryan P. Taylor³ · Michael L. Hancock³ · James T. Dalton⁵

Published online: 2 May 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made. Muscle wasting in cancer is an important and independent predictor of progressive functional impairment, decreased quality of life, and increased mortality. Although several therapeutic agents are currently in development for the treatment of muscle wasting or cachexia in cancer, the majority of these agents do not directly inhibit muscle loss. Selective androgen receptor modulators (SARMs) have the potential to increase lean body mass (LBM) and hence muscle mass, without the untoward side effects seen with traditional anabolic agents.

Enobosarm, a nonsteroidal SARM, is an agent in clinical development for prevention and treatment of muscle wasting in patients with cancer (POWER 1 and 2 trials). The POWER trials are two identically designed randomized, double-blind, placebo-controlled, multicenter, and multinational phase 3 trials to assess the efficacy of enobosarm for the prevention and treatment of muscle wasting in subjects initiating first-line chemotherapy for non-small-cell lung cancer (NSCLC). To assess enobosarm’s effect on both prevention and treatment of muscle wasting, no minimum weight loss is required. These pivotal trials have pioneered the methodological and regulatory fields exploring a therapeutic agent for cancer-associated muscle wasting, a process hereby described. In each POWER trial, subjects will receive placebo (n = 150) or enobosarm 3 mg (n = 150) orally once daily for 147 days. Physical function, assessed as stair climb power (SCP), and LBM, assessed by dual-energy X-ray absorptiometry (DXA), are the co-primary efficacy endpoints in both trials assessed at day 84. Based on extensive feedback from the US Food and Drug Administration (FDA), the co-primary endpoints will be analyzed as a responder analysis. To be considered a physical function responder, a subject must have ≥10 % improvement in physical function compared to baseline. To meet the definition of response on LBM, a subject must have demonstrated no loss of LBM compared with baseline. Secondary endpoints include durability of response assessed at day 147 in those responding at day 84. A combined overall survival analysis for both studies is considered a key secondary safety endpoint. The POWER trials design was established with extensive clinical input and collaboration with regulatory agencies. The efficacy endpoints are a result of this feedback and discussion of the threshold for clinical benefit in patients at risk for muscle wasting. Full results from these studies will soon be published and will further guide the development of future anabolic
trials. Clinical Trial ID: NCT01355484. https://clinicaltrials.gov/ct2/show/NCT01355484, NCT01355497. https://clinicaltrials.gov/ct2/show/NCT01355497?term=g300505&rank=1.

Keywords Muscle wasting · Sarcopenia · Selective androgen receptor modulator · Cachexia · Non-small-cell lung cancer · Enobosarm · Cachexia treatment · Cachexia therapy

Introduction

Cancer is a disease associated with severe muscle wasting caused by a variety of neural, nutritional, pro-inflammatory, and autocrine/endocrine factors that ultimately culminate in an imbalance between anabolism and catabolism. Emerging evidence suggests that muscle wasting in cancer can be an occult condition, present in individuals with normal or even high body weight [1]. Importantly, muscle wasting in cancer is common and an independent predictor of poorer physical function, higher incidence of chemotherapy-related toxicity, shorter time to tumor progression, increased length of hospital stay, and shorter survival [1–3].

Muscle wasting in cancer occurs across tumor sites and stages and is more pronounced and prevalent in patients with advanced gastrointestinal and/or lung cancer, where cachexia is often manifested. Muscle wasting in cancer patients represents a significant unmet medical need, as at the time of diagnosis, 50% of patients with advanced cancer will have skeletal muscle loss [4]. Furthermore, the proportion of patients experiencing muscle wasting at some point during the course of their malignancy increases to greater than 80% [5]. In addition, evidence suggests that up to 20% of all cancer deaths are directly caused by cachexia [6]. Muscle wasting in patients with NSCLC has been associated with decreased functional status, higher incidence of chemotherapy toxicity, and shorter survival.

When muscle wasting is accompanied by weight loss, a diagnosis of cachexia may be made. Cancer cachexia has been more recently defined as a complex syndrome characterized by ongoing skeletal muscle loss with or without an accompanying loss of fat mass [7, 8••]. This multifactorial syndrome cannot be completely reversed with conventional methods of nutritional supplementation or appetite stimulation and causes progressive functional impairment [8••].

The prevalence and significance of muscle wasting in cancer, as well as the lack of an effective treatment for this condition, underscores the importance of developing an effective therapeutic approach for the prevention and treatment of cancer-associated muscle wasting. Although megesterol acetate has been approved in some countries for cancer cachexia, the general consensus is that it has little effect on lean mass [9] and, to date, no pharmacologic treatments are approved for the prevention and treatment of muscle wasting. As muscle wasting has been primarily studied under the auspices of cancer cachexia, most appetite stimulants, anti-inflammatory and anabolic or nutritional agents have failed to effectively prevent or reverse this condition. Increasing nutritional delivery of energy may preserve or increase fat mass without increasing muscle mass, which could paradoxically be detrimental to patients [4, 10, 11•]. Some of the more successful attempts at treating cachexia-associated muscle wasting in cancer have resulted from anabolic androgenic steroids, which have been shown to increase protein synthesis and lean body mass (LBM) in wasting disorders [12–15]. However, in addition to promoting anabolism, these agents also have unfavorable androgenic effects including an increased risk of hepatic toxicity, acne, increased sebum production, and virilization and hirsutism in women, and potential concerns related to benign prostatic hyperplasia (BPH) and prostate cancer in men, that may outweigh their benefits [12, 16]. Ideally, a treatment should be able to produce anabolism selectively without the accompanying androgenic side effects, which has led to increased research on nonsteroidal, selective androgen receptor modulators, or SARMs [17].

Need for a Novel Study Design

In contrast to the development of new chemotherapies, there are no standard methods or outcomes for studying the prevention and treatment of muscle wasting and a novel study design was needed to demonstrate the clinical benefit of any therapeutic intervention for muscle wasting. In addition to assessing the efficacy of a drug to prevent and treat muscle wasting by measuring changes in physical function and LBM, it is essential to include safety endpoints related to disease burden and survival. Although the relationship between muscle mass and physical function is still obscure (i.e., the magnitude of LBM increase which is needed to promote an increase in function), physical function endpoints that are reflective of activities of daily living may be used to determine the clinical benefit associated with preserving or increasing LBM. Quality of life (QoL) also needs to be assessed in these trials, especially in patients who demonstrate a response on the physical function assessment. Available methods that measure the impact of anorexia, fatigue, or cachexia on a patient’s quality of life include the Functional Assessment of Cancer Therapy (FACT) questionnaire and its subscales [18, 19].

Novel Drug: Enobosarm

Enobosarm (GTx-024; GTx, Inc., Memphis, TN) is an orally bioavailable nonsteroidal SARM [20]. The potential of enobosarm for clinical utility was demonstrated...
by its selective activity in anabolic tissues at low doses in preclinical trials [21]. In the clinical setting, the use of enobosarm led to significant improvements in LBM and physical function in a phase 2, double-blind, placebo-controlled study in healthy postmenopausal women and elderly men [20]. In a phase 2b, double blind, placebo-controlled study, enobosarm treatment was well tolerated and led to significantly improved LBM, physical function, and quality of life in men older than 45 years and postmenopausal women with non-small-cell lung cancer (NSCLC), colorectal cancer, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, or breast cancer [22]. Androgenic adverse events, including negative effects on the prostate, virilization, and hirsutism, have not been reported [20].

Building on these findings, the phase 3 Prevention and treatment of muscle Wasting in patients with cancer (POWER) studies (POWER 1 and POWER 2) are designed to assess the efficacy and safety of enobosarm for the prevention and treatment of muscle wasting in patients undergoing first-line chemotherapy for NSCLC, with the ultimate goal of demonstrating the clinical benefit of enobosarm on physical function and LBM. Consultation occurred with several agencies: the US Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA; UK), and the Medical Products Agency (MPA; Sweden), at different stages of the study development. MHRA and MPA were consulted after the protocol was finished but before the study’s standard operation procedure (SAP) was written. Consultation with them was ultimately responsible for the inclusion of the continuous variable analyses.

**Design of the POWER Trials**

As mentioned above, two identical trials were designed to evaluate the efficacy and safety of enobosarm for the prevention and treatment of muscle wasting in patients with NSCLC undergoing first-line platinum-based chemotherapy either with a taxane (POWER 1) or non-taxane (POWER 2). A range of potential standard chemotherapy regimens allow the treatment of the study population to reflect standard of care at the community level, including the most common chemotherapy in this setting. Additionally, similar outcomes were expected across these chemotherapy regimens in terms of toxicity and clinical response within each trial, reducing potential heterogeneity associated with treatment within the taxane trial and within the non-taxane trial. First-line treatment with tyrosine kinase inhibitors is prohibited in these studies to maintain a homogenous patient population in terms of first-line chemotherapy and avoid any potential concerns related to the ability of the tyrosine kinase inhibitors to exacerbate muscle wasting [23]. Importantly, this exclusion criterion allows study participation by the majority of patients with NSCLC undergoing first-line treatment and allows subjects to receive tyrosine kinase inhibitors if clinically warranted after potential tumor progression during the trials (failed first-line chemotherapy).

As muscle wasting has multifactorial etiologies that differ depending on the type of malignancy with which it is associated (pancreatic cancer vs head and neck cancer vs esophageal cancer, as examples), the success of a phase 3 clinical trial depends on further limiting heterogeneity by studying one specific tumor type at a time. NSCLC was chosen as a representative cancer for these phase 3 studies primarily because lung cancer is the leading cause of cancer death in the western world, including the USA [24] and up to 85–90% of lung cancer cases are NSCLC [25]. There were approximately 1.8 million new cases of lung cancer reported worldwide in 2012 [26]. Approximately 50% of patients with NSCLC and greater than 60% of men with NSCLC have already developed severe muscle wasting by the time their malignancy is diagnosed [4]. Moreover, in the preceding phase 2b trial of enobosarm in patients with NSCLC, significant losses in LBM occurred over the course of the study (4 months) in the placebo arm, while enobosarm improved physical function and LBM.

Importantly, the FDA is in agreement with including NSCLC as an appropriate cancer type to target in the phase 3 trial as these patients would likely present with a median survival of a sufficient duration to measure the effect of the therapy. As other cancer types are associated with more aggressive muscle wasting (e.g., pancreatic cancer), the shorter overall survival represents a potential challenge for a 5-month intervention.

**Patients**

The full inclusion and exclusion criteria for POWER 1 and POWER 2 can be found in Table 1. In short, postmenopausal females and males >45 years of age with a diagnosis of stage III or IV NSCLC prior to the initiation of first-line chemotherapy are eligible. Subjects do not have to meet a minimum or maximum amount of weight loss at baseline to be eligible for the study. This allows the inclusion of patients with and without muscle wasting prior to study entry, allowing for the evaluation of both prevention and treatment of this condition. The trial was conducted in 60 academic and experienced community sites in Eastern Europe, South America, and North America.

**Overall Study Design**

POWER 1 and POWER 2 are identically designed, phase 3, randomized, double-blind, placebo-controlled, multicenter, multinational trials (Fig. 1). A total of 300 patients are to be
enrolled into each study (see statistical section for details). Randomization is as follows: 1:1 ratio to either placebo ($n = 150$) or enobosarm 3 mg ($n = 150$), with patients stratified to balance the distribution of first-line chemotherapy regimens, gender, and NSCLC stage (III vs IV). Study treatment will be administered orally once a day for up to 147 days, with follow-up of only survival continuing after day 147.

### Endpoints and Justification for Response Criteria

A comprehensive list of all efficacy and safety endpoints can be found in Table 2. The co-primary endpoints were physical function and LBM response assessed at baseline, day-42, day-84, and day-147 visits. A patient is deemed to have a physical function response if a $\geq 10\%$ increase in stair climb power at the day-84 visit is observed as compared with baseline. This threshold was established based on clinical meaningfulness from previous literature [27, 28]. A patient is deemed to have had a LBM response if their LBM at the day-84 visit is the same as or higher than their LBM at baseline.

### Rationale for Physical Function Tests

Physical function tests have been utilized in the approval of medications to treat diseases associated with functional limitations such as multiple sclerosis, pulmonary arterial hypertension, and HIV-associated wasting [29–31].

The stair climb test was chosen for these trials based on its association with everyday living and is associated with strength, balance, mobility, speed, and endurance [32]. The stair climb power has been a physical function method of choice on previously conducted clinical studies in populations with or at risk for muscle loss (including NSCLC patients). It is a simple and safe measure associated with measures of lower-limb muscle strength and power and functional performance in older patients.

---

Table 1  POWER 1 and POWER 2 inclusion and exclusion criteria

| Inclusion | Exclusion |
|-----------|-----------|
| Voluntary, signed informed consent | Clinically significant concurrent illness that would interfere with protocol compliance or follow-up (investigator judgment) |
| BMI $\leq 32$ and weight $<300$ lb ($<136$ kg) | ALT/SGPT or AST/SGOT $>1.5$ times the ULN without and $>5$ times the ULN, evidence of liver metastases |
| Diagnosis of stage III or IV NSCLC | Alkaline phosphatase $>3$ times the ULN and/or total bilirubin $>2$ mg/dL at baseline |
| First-line chemotherapy not yet started | Biologic agents or kinase inhibitors in chemotherapy regimen including, but not limited to bevacizumab, gefitinib, and erlotinib |
| Planned first-line chemotherapy regimen is platinum plus a taxane (POWER 1) or platinum plus a non-taxane agent (POWER 2) | Uncontrolled hypertension, congestive heart failure, or angina |
| Screening to occur $\geq 4$ weeks (28 days) postsurgery (in surgical cases) | Stage 4 chronic obstructive pulmonary disease |
| Life expectancy $>6$ months | HBsAg positive for hepatitis B, unless diagnosis was $>10$ years prior to enrollment with no evidence of active liver disease |
| ECOG score $\leq 1$ | Positive screen for hepatitis C antibody, hepatitis A antibody IgM, or HIV |
| Serum creatinine $\leq 2.0$ mg/dL | Use of testosterone, oxandrolone, testosterone-like androgenic agents, or antiandrogens within 30 days of study (requiring permission in cases of long-term depot within 6 months) |
| Men: aged $\geq 30$ years | Current use of megestrol acetate, dronabinol, medical marijuana, or any prescription medication intended to increase appetite or treat unintentional weight loss |
| Women: aged $\geq 30$ years with clinical confirmation of postmenopausal status | Baseline stair climb time $\geq 30$ s (mean of two stair climb tests) |
| Men: agree to use a double-barrier method of contraception during and 3 months after study | Active cancer, other than NSCLC or nonmelanoma carcinoma of the skin, within the past 2 years |
| Men: serum PSA $\leq 4.0$ ng/mL or biopsy negative for prostate cancer within 6 months | |

---

ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECOG Eastern Cooperative Oncology Group, HBsAg hepatitis B surface antigen, IgM immunoglobulin M, NSCLC non-small cell lung cancer, POWER Prevention and Treatment Of muscle Wasting in patients with cancER, PSA prostate-specific antigen, SGOT serum glutamic oxaloacetic transaminase, SGPT serum glutamic pyruvic transaminase, ULN upper limit of normal
adults [33]. Decreases in stair climb power in elderly patients have been associated with detrimental changes in balance and falls and morbidity and mortality, whereas increases have been associated with improvements in QOL [32].

Stair climb power is calculated as power (watts) = work/time = force × velocity. In addition to strength, it takes into consideration a constellation of muscle-related attributes including balance, mobility, and endurance [32]. Due to the level of physical intensity required to climb stairs, increases in stair climb power should equate to similar or greater improvements in other less physically intense daily activities that are either short in duration or utilize smaller muscle groups (i.e., walking a short distance, rising to a standing position from a chair, or lifting or carrying household items). Furthermore, the stair climb test is a direct measure and is a well-accepted, reproducible, portable, and objective measure of physical function [32].

Regardless of the physical function test used, thresholds of clinically meaningful change have been established. A minimally clinically meaningful change in physical function is a 5 % increase from baseline and a substantial clinically meaningful change is a 10 % increase from baseline. Published literature in healthy elderly and mobility limited subjects has correlated measures of physical function with clinically meaningful changes as established in the Short Physical Performance Battery (SPPB). In a large randomized trial with adults aged 70–89 (N=424) Kwon et al. utilized 400-m walk and gait speed and demonstrated that a 4–4.5 % improvement in physical function translates into “minimally meaningful” change while an improvement of 10 % represents a “substantial meaningful” change [27]. Perera et al. showed similar results with gait speed, 6-min walk distance, and self-reported mobility in older adults with mobility disabilities (N=492) concluding that an improvement in performance of 6–8 % represents a “small meaningful change” and 11–17 % a “substantial meaningful change” [28]. These studies define thresholds for “minimally meaningful” and “substantial meaningful” clinical change that can be applied regardless of the physical function test used.

**Rationale for Body Composition Assessment**

Although CT, MRI, and DXA are the methods of choice for the assessment of lean and adipose tissue compartments [34–39], DXA was selected as a method of choice for the POWER trials due to its reliability and availability in clinical settings (typically used for the assessment of osteoporosis and its cost-efficiency with minimal radiation exposure) [40, 41]. Additionally, DXA measures are strongly correlated with the state-of-the-art CT or MRI [42–46]. Since skeletal muscle is such an important component of the LBM compartment, changes in DXA-assessed LBM reflect changes in skeletal muscle mass [39, 47].

LBM response is defined as no loss in LBM at the day-84 visit compared to baseline. DXA scans of the whole body are performed at approximately the same time of day and by the same technician, with the patient in a similar position using the same DXA scanner and software version. DXA scans will be read centrally by Synarc Imaging (www.synarc.com).
CT scans will also be performed at the days-84 and day-147 visits to assess tumor status, using contrast of the chest and abdomen, including the liver and adrenal glands. If subjects have brain metastases at baseline, CT or MRI will also be assessed at these time points.

### Additional Assessments

| Key | Study day |
|-----|-----------|
| US Food and Drug Administration: coprimary | |
| 10 % Increase in physical function via stair climb power | 84 |
| No loss of total LBM | 84 |
| MHRA/MPA: primary and key secondary | |
| Change in physical function via stair climb power; continuous variable analysis | |
| Change in total LBM; continuous variable analysis | |

#### Secondary

| Physical function via stair climb power (day 84 responders only) | 147 |
| Total LBM (day 84 responders only) | 147 |
| Change in stair climb power from baseline | 84 |
| Change in LBM from baseline | 84 |
| Overall survival (data pooled from both studies) | N/A |

#### Tertiary

| Healthcare resource utilization | Study day(s) |
| Percentage of adherence to baseline chemotherapy regimen | 21, 42, 63, 84, 105, 126, 147 |
| Change in total body weight | 0, 21, 42, 63, 84, 105, 126, 147 |
| QOL via FAACT-12® | 0, 42, 84, 147 |
| QOL via FACIT Fatigue Scale® | 0, 42, 84, 147 |
| QOL via PROMIS® Physical Functioning Short Form 10a | 0, 42, 84, 147 |
| QOL via PROMIS® Emotional Distress-Depression Short Form 8b | 0, 42, 84, 147 |
| QOL via EQ-5D-5 L™ | 0, 42, 84, 147 |
| 5 % Increase in physical function via stair climb power | 84 |
| Chemotherapy tolerability | 21, 42, 63, 84, 105, 126, 147 |

#### Safety

| Routine safety assessments (adverse events, chemistries, urinalysis, hematology) | 0, 21, 42, 63, 84, 105, 126, 147 |
| Overall survival | N/A |
| Serum hormone levels | 0, 84, 147 |
| Hair growth (women) | 0, 84, 147 |
| Serum PSA levels (men) | 0, 21, 42, 63, 84, 105, 126, 147 |
| ECOG status | 84, 147 |
| Tumor progression by RECIST 1.1 classification | 84, 147 |

**MHRA** Medicines and Healthcare Products Regulatory Agency, **MPA** Medical Products Agency, **ECOG** Eastern Cooperative Oncology Group, **FAACT** Functional Assessment of Anorexia and Cachexia Therapies, **FACIT** Functional Assessment of Chronic Illness Therapy, **QOL** quality of life, **PROMIS** Patient-Reported Outcomes Measurement Information System, **PSA** prostate-specific antigen, **RECIST** Response Evaluation Criteria In Solid Tumors

*a* Mean change to be calculated for each treatment arm

*b* Change from baseline includes initiation of second-line chemotherapy regimen

*c* Routine urinalysis was performed only on days 0, 84, and 147
Form 8b, and the EQ-5D-5 L™ (Table 2). These QoL instruments were intended to provide insights regarding how the patients’ health, physical functioning, and ability to care for themselves have been affected by their disease, as well as their level of emotional distress and fatigue and perceptions about the importance of various disease characteristics.

Statistical Methods

The two trials differ only in the choices of chemotherapy. Both trials will evaluate the same endpoints of lean body mass and stair climb power. After discussion with US and European regulatory authorities, it was decided that different methods of analysis of the SCP and LBM endpoints would be used in the two regions.

For the US authorities, a responder analysis will be performed for LBM and SCP as coprimary endpoints.

For European authorities, SCP will be the primary endpoint and LBM secondary. Both will be analyzed by longitudinal analysis of percent change from baseline through days 84 and 147. Both analyses have different strengths and weaknesses, but will be complementary to understanding the treatment outcomes for enobosarm in the population and are further described below.

The design proposed to US regulatory authorities is a responder analysis consisting of co-primary end points, one for physical function and one for LBM. Physical function response is defined as ≥10 % improvement from baseline to day 84, and LBM response is defined as no loss of LBM from baseline to day 84. Non-response is a failure to meet the response definition or not having the day-84 assessment for any reason. Missing data is accounted for by this definition of non-response. The design assumes a proportion of response among treated subjects of 0.20 above the control response proportion for each of the physical function and LBM endpoints. Retrospective application of the response definitions to the subset of NSCLC subjects in the predecessor phase 2b trial showed the maximum control response was 25 % for the LBM endpoint (19 % for SCP); this was inflated to 30 %, that the difference in the proportions responding to both end points was approximately 0.20, and with other parameters α = 0.05 and power = 90 %, the sample size required was 124 subjects per arm. Built into the computation above was the assumption that 30 % of subjects would be considered non-responders due to missing the day 84 primary endpoint assessment. FDA requested that the sample size be increased to 150 subjects per arm for the purposes of the safety data base. The 0.20 difference in proportion of response between the two arms covers a wide range of possible control response proportions so that for control, response proportions from 0.20 to 0.75 all have power >90 % to detect a 0.20 difference at α = 0.05 with 150 subjects per arm. Specifically, at the aforementioned 0.30 control, response power is 93.3 %. Overall study success for US purposes is defined as rejecting the null hypothesis for both primary endpoints using a two-sided type I error probability of 0.05 for each. Considering the need for both coprimaries to be statistically significant, the power for each trial is at least 86.5 % under the assumption of no correlation between endpoints.

Each endpoint will be tested separately for significance using a Monte Carlo approximation to the exact Cochran-Mantel-Haenszel test stratified by chemotherapy regimen (platinum plus paclitaxel or platinum plus docetaxel for POWER 1 and platinum plus gemcitabine or platinum plus pemetrexed or platinum plus vinorelbin for POWER 2), gender, and cancer stage (III or IV). Importantly, a patient may be a responder for one endpoint but not the other. Because all subjects randomized and treated will have a response classification, the primary analysis is intent-to-treat.

Analyses associated with the continuous form of the data, rather than the dichotomous form of the data used in the responder analyses, will be used to analyze secondary endpoints. As noted, the percentage change in power will be the sole primary endpoint (stair climb power) for European regulatory authorities. Random coefficients models (RCM)—also termed mixed model repeated measures (MMRM) analyses—will be used in order to include all available data, including the day 42 assessment, for the physical function endpoint including replicates, study day of assessment, treatment arm, and the interaction between treatment arm and study day of assessment. A significant interaction (p < 0.05) would indicate significantly different slopes (rates of change per day) between the enobosarm-treated arm and the placebo arm. The same methodology will be applied to the continuous form of the LBM data; however, there are no replicates of DXA results at each time point, unlike the physical function test. For each of the physical function and LBM endpoints, an MMRM analysis that compares the mean of post-baseline measures between the two arms will be undertaken as well. Hochberg’s methodology for controlling alpha will be applied, so that, e.g., if the slope analysis are not significant for say physical function, testing will move to the post-baseline mean analysis but the alpha level required for a significant result will be α = 0.025, and the physical function endpoint will be considered significant. Hierarchical testing will be used to control alpha across all of the secondary endpoints so that if an endpoint is deemed non-significant, i.e., both the slope and post-baseline mean analyses are non-significant, formal statistical testing will halt, and all further secondary endpoints below that endpoint in the hierarchy will be considered non-significant.

Responder analyses will be undertaken for QoL instruments that have individual changes that are considered a
response, as already described for the coprimary endpoints. For quality-of-life instruments without a defined response, appropriate parametric or nonparametric tests will be used to compare differences in distributions. Additional sensitivity and subgroup analyses are planned.

Survival analysis will be conducted as a predefined safety endpoint of the clinical program to ensure that there was no detrimental effect of enobosarm on the underlying cancer. Additionally, the survival outcome data will be pooled to formally assess superior survival in the enobosarm group compared with placebo. The total number of patients expected for the survival assessment is 600; the survival assessment is event-driven and will require at least 450 deaths. Survival will be estimated by the Kaplan–Meier method; differences in survival distributions will be compared with a stratified log-rank test, stratified by chemotherapy (taxane, non-taxane; effectively stratifying by trial), sex, and stage. It is projected that the 450 deaths will be realized at approximately 2.84 years after accrual of the first patient. Although the trials are not prospectively powered to detect a survival difference, if median survival in the combined placebo arm is assumed to be 1 year and uniform accrual of all 600 patients occurs in 1 year (both trials starting at approximately the same time), then the test would have 86.6 % power to detect a hazard ratio of ≤0.75. The actual critical hazard ratio estimate of ≤0.831 would be associated with a significant ($p<0.05$) result and lead to a conclusion of survival superiority.

**Discussion and Conclusions**

In light of the profound unmet medical need for the prevention and treatment of muscle wasting in patients with cancer, a number of agents, including SARMs, are under development for patients with cancer who are prone to muscle wasting and cachexia. The POWER trials for enobosarm are the first phase 3 clinical trials to assess a SARM for muscle wasting in patients with cancer and have addressed the need for novel study design(s) with relevant endpoints to establish meaningful clinical benefit for patients. Results from the POWER trials will soon be released and will provide the first evidence collected prospectively on the natural history of muscle wasting in patients receiving first-line chemotherapy and the magnitude and impact of a SARM used for the treatment of muscle wasting in NSCLC. Furthermore, results from the trials will be used to critically evaluate the hereby described study design.

POWER 1 and POWER 2 include subjects with no minimum or maximum amount of weight loss at baseline so that both prevention and treatment of muscle wasting can be assessed as well as the prevalence of cachexia among these patients according to recently proposed diagnostic criteria. The majority of clinical trials investigating treatments for muscle wasting or cachexia specify a minimum amount of weight loss at baseline, limiting their ability to assess the preventive potential of a specific regimen [13–15, 31, 48–52]. The importance of prevention is underscored by evidence that muscle wasting begins before the manifestation of any outward clinical signs or symptoms, including overt weight loss [53]. There is evidence to suggest that proteasome activity (an indicator of protein degradation) was increased in muscle biopsies taken from patients with gastric cancer, including patients who had not yet exhibited weight loss [54].

In addition to studying subjects who have not yet lost weight, it is also important to characterize any changes in weight that do occur throughout a study. Weight loss or gain can reflect changes in adipose tissue, skeletal muscle, or both; therefore, in order to determine whether an anabolic therapy is affecting muscle wasting, it is necessary to measure changes in body composition (i.e., LBM) at baseline and during treatment (7, 8). As CT scans have been previously acquired as part of the medical diagnosis/treatment (as discussed previously), an additional analysis of body composition by this technique is being planned [55].

An additional aspect to be evaluated in the POWER trials was the choice of functional assessments; including the stair climb test and a variety of patient-reported mental, emotional, social, and physical well-being instruments. Although defined by loss in muscle mass, much of the burden of cachexia is due to loss of function that is reflected in poor outcomes on the aforementioned functional parameters. A palliative approach addresses these by focusing on both the disease and symptoms caused by the disease, within a patient/family-focused model [56]. For this reason, the POWER trials incorporate a wide variety of tests of functioning and QoL—such as stair climb power and five separate QoL tools—to illuminate the full range of each cancer patient’s experience in light of cancer-driven cachexia [18, 19]. In the phase 2b study of enobosarm, LBM increased significantly in the 1- and 3-mg treatment groups; stair climb results also improved from baseline, by 18.0 % in the 1-mg arm and by 21.7 % in the 3-mg arm [22••]. The use of coprimary endpoints related to LBM and stair climb performance in the POWER studies may allow more definitive analysis of the relationship between these two measures.

It has been shown that initiating palliative care measures early during cancer disease trajectory can result in prolonged survival and clinically meaningful improvements in QoL and mood in patients with advanced NSCLC [57]. While the primary objectives of the POWER studies deal with body composition and physical function, tumor progression and overall survival data will also be of great interest. Although enobosarm is being studied for the prevention and treatment of muscle wasting, the potential interplay between muscle wasting and disease progression may be of interest in these trials and in future supporting studies [58].
The POWER trials include patients with NSCLC as the first population for treatment with enobosarm, but patients with other cancer types may also benefit from enobosarm for muscle wasting, which awaits confirmation in additional trials. Cancer is a highly catabolic condition and typically more severely manifested in colorectal, gastrointestinal, and pancreatic cancers even prior to the initiation of chemotherapy [59], making patients with these tumor types of particular interest for future muscle wasting and cachexia trials.

While the design of the POWER trials assesses the ability of enobosarm to prevent and treat muscle wasting in a population being treated with standard chemotherapy, future research may be warranted to include patients using newer, more targeted therapies. For example, with the approval of several tyrosine kinase inhibitors, in lung cancer, renal cell carcinoma, and other malignancies, it remains to be determined whether a SARM can benefit patients receiving these treatments. Furthermore, it has been found that these targeted cancer treatments themselves may be associated with muscle wasting, so carefully controlled studies in these settings will be needed [23].

As research in muscle wasting disorders progresses, we may see the advent of combination therapy regimens. Since there are both hypoanabolic and hypercatabolic processes at work in cachexia in a multifactorial fashion, it may be prudent to study the effects of combining an anabolic agent with an antagonist of catabolic mediators [60]. Given that the best outcome would be prevention of muscle wasting, and hence cancer cachexia, future research should focus on both prevention and treatment of this condition. It is anticipated that outcomes from the POWER 1 and POWER 2 trials will be a critical step in not only addressing a pressing unmet medical need for additional supportive care, but also significantly informing future research directions for enobosarm and other trials. Notably, several underlying clinical conditions can result in muscle wasting with and without associated cachexia, such as acquired immune deficiency syndrome (AIDS), chronic heart failure, chronic obstructive pulmonary disease (COPD), chronic renal failure, chronic infection and sepsis, and cancer [7, 61], all of which can benefit from anabolic therapy.

POWER 1 and POWER 2 Trial Status

The POWER studies were conceived and designed in 2011, and recruitment commenced the same year. Recruitment was completed in 2013, with results being prepared for publication.

Acknowledgments Editorial support for this manuscript was provided by Complete Publication Solutions, LLC; this support was funded by GTx, Inc. The trial herein described was initiated, designed, and funded by GTx, Inc. JC had input to the initial trial design and provided ongoing oversight during the study and will participate in data review, analysis, and publication. CMP and RG are Steering Committee Members. We also thank Sarah Purcell for her assistance in organizing the references in this manuscript.

Compliance with Ethical Standards

Conflict of Interest Jeffreya Crawford received research funding through a grant from GTx, Inc. to Duke University to conduct the trials in this article.

Carla M.M. Prado is a Steering Committee Member and has received research funding from GTx, Inc.

Mary Ann Johnston is an employee of GTx, Inc., and therefore owns stock and has stock options.

Richard J. Gralla is a Steering Committee Member and has received compensation from Helsinn for service as a scientific consultant.

Ryan P. Taylor is an employee of GTx, Inc., and therefore owns stock and has stock options.

Michael L. Hancock is an employee of GTx, Inc., and therefore owns stock and has stock options, and has a patent WO 2015/061724 A1 pending.

James T. Dalton was an employee of GTx, Inc., and therefore owned stock and had stock options, and is currently a paid consultant to GTx, Inc. In addition, Dr. Dalton has US and international patents on enobosarm and methods of use and receives royalties paid by GTx to the University of Tennessee Research Foundation.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Funding Source This work was supported by GTx, Inc.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
** Of outstanding importance

1. Prado CM, Maia YL, Ormsbee M, Sawyer MB, Baracos VE. Assessment of nutritional status in cancer—the relationship between body composition and pharmacokinetics. Anti Cancer Agents Med Chem. 2013;13(8):1197–208.
2. Prado CM. Body composition in chemotherapy: the promising role of CT scans. Curr Opin Clin Nutr Metab Care. 2013;16(5):525–33.
3. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009;15(8):2920–6.
4. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91(4):1133–7s.

5. Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ (Clinical research ed). 1997;315(7117):1219–22.

6. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11(4):400–7.

7. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clinical nutrition (Edinburgh, Scotland). 2008;27(6):793–9.

8. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. The framework for the definition and classification of cancer cachexia was presented in this paper.

9. Adrad-bron A, Elsner F, Trottenberg P, Strasser F, Baracos V, Fearon K. Clinical practice guidelines on cancer cachexia in advanced cancer patients with a focus on refractory cachexia. Department of Palliative Medicine/European Palliative Care Research Collaborative. 2010.

10. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010;91(4):1121S–7S.

11. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr. 2011;98(4):1012–9. This study highlights that contrary to popular belief, muscle wasting in cancer is reversible; therapy should nonetheless include patients earlier on in disease trajectory when the window for anabolism is opened.

12. Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86(11):5108–17.

13. Lesser GJ, Case D, Ottery F, McQuillon R, Choksi JK, Sanders G, et al. A phase II randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. J Clin Oncol. 2008;26(suppl):9513.

14. Mwamburi DM, Gerrior J, Wilson IB, Chang H, Guttridge D, et al. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11(4):400–7.

15. Webster K, Cell a D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.

16. Dalton JT, Bannister KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTX-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachex Sarcoenemia Muscle. 2011;2(3):153–61.

17. Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT. The para substituent of S-3- (phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionimides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther. 2005;315(1):230–9.

18. Dobs AS, Bocca RV, Crotto CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45. This study was the first clinical trial to examine safety and efficacy of a selective androgen receptor modulator for cancer-induced muscle wasting.

19. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(6):1054–60.

20. American Cancer Society. Cancer Facts & Figures. Atlanta, GA: 2012.

21. American Cancer Society. What is non-small cell lung cancer? Atlanta, GA: 2012.

22. World Health Organization GLOBOCAN 2012. Estimated cancer incidence, mortality, and prevalence worldwide in 2012. 2012.

23. Kwon S, Perera S, Pahor M, Katula JA, King AC, Grossi EJ, et al. What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging. 2009;13(6):538–44.

24. Dobs AS, Bocca RV, Crotto CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45. This study was the first clinical trial to examine safety and efficacy of a selective androgen receptor modulator for cancer-induced muscle wasting.

25. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(6):1054–60.

26. American Cancer Society. Cancer Facts & Figures. Atlanta, GA: 2012.

27. World Health Organization GLOBOCAN 2012. Estimated cancer incidence, mortality, and prevalence worldwide in 2012. 2012.

28. Kwon S, Perera S, Pahor M, Katula JA, King AC, Grossi EJ, et al. What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging. 2009;13(6):538–44.

29. Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O'Brien F, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35(5):743–9.

30. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral farnipamide in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732–8.

31. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.

32. Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O'Brien F, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35(5):743–75.

33. Bean JF, Kiely DK, LaRose S, Allan J, Frontera WR. Is stair climb power a clinically relevant measure of leg power impairments in at-risk older adults? Arch Phys Med Rehabil. 2007;88(5):604–9.

34. Perera S, Eng JJ, MacIntyre DL, Road JD, Reid WD. Associations of muscle function with seven performance measures in older adults. J Am Geriatr Soc. 2008;56(5):785–95.

35. Rüüsnner S, Bo WJ, Hilbrandt E, Hinson W, Karstaedt N, Santo Pf, et al. Adipose tissue determinations in cadavers-a
comparison between cross-sectional planimetry and computed tomography. Int J Obes. 1990;14:893–902.

36. Slosman DO, Caserjiz, Pichard C, Roche T, Fery F, Rizzoli R, et al. Assessment of whole body composition with dual-energy X-ray absorptiometry. Radiology. 1992;185:593–8.

37. Ioanidou E, Padilla J, Wang J, Heymsfield SB, Thornton JC, Horlick M, et al. Pencil-beam versus fan-beam dual-energy X-ray absorptiometry comparisons across four systems: appendicular lean soft tissue. Acta Diabetol. 2003;40:583–5.

38. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr. 2012;31(5):583–601.

39. Prado CM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. J Parenter Enteral Nutr. 2014;38(4):940–53.

40. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom. 2007;10:102–10.

41. Liu H, Paige NM, Goldwieg CL, Wong E, Zhou A, Suttrop MJ, et al. Screening for osteoporosis in Men: a systematic review for an American College of Physicians Guideline. Ann Intern Med. 2008;148:685–701.

42. Fuller NJ, Hardingham CR, Graves M, Sceaton N, Dixon AK, Ward LC, et al. Assessment of limb muscle and adipose tissue by dual-energy X-ray absorptiometry using magnetic resonance imaging for comparison. Int J Obes. 1999;23:1295–302.

43. Glickman SG, Marn CS, Supiano MA, Dangel DR. Validity and reliability of dual-energy X-ray absorptiometry for the assessment of abdominal adiposity. J Appl Physiol. 2004;97:509–14.

44. Levine JA, Abboud L, Barry M, Reed JE, Sheedy PF, Jensen MD. Measuring leg muscle and fat mass in humans: comparison of CT and dual-energy X-ray absorptiometry. J Appl Physiol. 2000;88:452–6.

45. Lane JT, Mack-Shipman LR, Anderson JC, Moore TE, Erickson JM, Ford TC, et al. Comparison of CT and dual-energy DEXA using a modified trunk compartment in the measurement of abdominal fat. Endocrine. 2005;27:295–9.

46. Visser M, Fuerst T, Lang T, Salamone L, Harris TB. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, aging, and body composition study-dual-energy X-ray absorptiometry and body composition working group. J Appl Physiol. 1999;87:1513–20.

47. Heymsfield SB, Gallagher D, Kotler DP, Wang Z, Allison DB, Heshka S. Body-size dependence of resting energy expenditure can be attributed to nonenergetic homogeneity of fat-free mass. Am J Physiol Endocrinol Metab. 2002;282(1):E132–8.

48. Gordon JN, Trebley TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54(4):540–5.

49. Mantovani G, Maccio A, Madeddu C, Serpe R, Antoni G, Massa E, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med. 2010;88(1):85–92.

50. Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessi M, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15(2):200–11.

51. Stewart Coats AJ, Srinivasan V, Surendran J, Chiramanah, Vangipuram SR, Bhatt NN, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. 2011;2(4):201–7.

52. ClinicalTrials.gov. Oxandrolone compared with megestrol in preventing weight loss in patients receiving chemotherapy for cancer 2012 [updated June 22, 2012; cited 2012 September 6]. NCT00070148. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00070148?term=NCT00070148&rank=1.

53. Prado CM, Siervo M, Mire E, Heymsfield SB, Stephan BC, Broyles S, et al. A population-based approach to define body-composition phenotypes. Am J Clin Nutr. 2014;99(6):1369–77.

54. Bossola M, Muscatioli M, Costelli P, Greico G, Bonelli G, Pacelli F, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg. 2003;237(3):384–9.

55. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 2009;3(4):269–75.

56. MacDonald N. Terminology in cancer cachexia: importance and status. Curr Opin Clin Nutr Metab Care. 2012;15(3):220–5.

57. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.

58. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153–66.

59. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491–7.

60. Baracos VE. Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies. Cancer. 2001;92(6 Suppl):1669–77.

61. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83(4):735–43.